Your browser doesn't support javascript.
loading
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
Lau, Peter Kar Han; Feran, Breon; Smith, Lorey; Lasocki, Arian; Molania, Ramyar; Smith, Kortnye; Weppler, Alison; Angel, Christopher; Kee, Damien; Bhave, Prachi; Lee, Belinda; Young, Richard J; Iravani, Amir; Yeang, Hanxian Aw; Vergara, Ismael A; Kok, David; Drummond, Kate; Neeson, Paul Joseph; Sheppard, Karen E; Papenfuss, Tony; Solomon, Benjamin J; Sandhu, Shahneen; McArthur, Grant A.
Afiliação
  • Lau PKH; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Feran B; Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Smith L; Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Lasocki A; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Molania R; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Smith K; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Weppler A; Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Angel C; Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Kee D; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Bhave P; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Lee B; Department of Histopathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Young RJ; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Iravani A; Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Yeang HA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Vergara IA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Kok D; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Drummond K; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Neeson PJ; Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sheppard KE; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Papenfuss T; Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Solomon BJ; Melanoma Institute Australia, North Sydney, New South Wales, Australia.
  • Sandhu S; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • McArthur GA; Department of Neurosurgery, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
J Immunother Cancer ; 9(10)2021 10.
Article em En | MEDLINE | ID: mdl-34625515
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Quinases de Proteína Quinase Ativadas por Mitógeno / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Receptor de Morte Celular Programada 1 / Ipilimumab / Nivolumabe / Melanoma Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Quinases de Proteína Quinase Ativadas por Mitógeno / Proteínas Proto-Oncogênicas B-raf / Inibidores de Proteínas Quinases / Receptor de Morte Celular Programada 1 / Ipilimumab / Nivolumabe / Melanoma Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article